Evidence map›Paper›PMID 37577049›Full record

ArticleIDCases2023

Case report: First case of

Thomas Schwartz, Dieuwertje Hoornstra, Erik Øie, Joppe Hovius, Hanne Quarsten

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in IDCases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
1.1field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 4 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 2 countries.

Thomas SchwartzDepartment of Internal Medicine, Diakonhjemmet Hospital, Oslo, Norway.
Dieuwertje HoornstraCenter for Experimental and Molecular Medicine, Amsterdam University Medical Centers, Location Academic Medical Center, Amsterdam, the Netherlands.
Erik ØieDepartment of Internal Medicine, Diakonhjemmet Hospital, Oslo, Norway.
Joppe HoviusCenter for Experimental and Molecular Medicine, Amsterdam University Medical Centers, Location Academic Medical Center, Amsterdam, the Netherlands.
Hanne QuarstenDepartment of Medical Microbiology, Sørlandet Hospital, Kristiansand, Norway.
Amsterdam UMC Location University of Amsterdam · NLDiakonhjemmet Hospital · NOOsloMet – Oslo Metropolitan University · NOSørlandet Sykehus · NO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Tick-borne disease caused by Case presentation: A 70-year-old female receiving immunosuppressive rituximab therapy presented with frontal headache, dizziness, nausea, vomiting and chills. Clinical laboratory blood analyses were normal. Cerebrospinal fluid (CSF) was translucent and analysis showed increased leucocyte count (187 10 Conclusions: To our knowledge, we present the first patient with BMD-associated meningitis in Norway, one of eight cases reported worldwide. The patient had mild symptoms and received an early diagnosis. A more severe progression or relapse of disease may have been prevented by antibiotic treatment. BMD should be considered as causes of aseptic meningitis, especially in immunosuppressed patients living in endemic areas.

Indexed as

Aseptic meningitisBorrelia miyamotoiOpportunistic infectionsRituximabTick-borne disease

Identifiers

PMID37577049
PMCPMC10412827
OpenAlexW4385431322

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.